State-of-the-Art Paper
Resting Heart Rate in Cardiovascular Disease

https://doi.org/10.1016/j.jacc.2007.04.079Get rights and content
Under an Elsevier user license
open archive

The importance of resting heart rate (HR) as a prognostic factor and potential therapeutic target is not yet generally accepted. Recent large epidemiologic studies have confirmed earlier studies that showed resting HR to be an independent predictor of cardiovascular and all-cause mortality in men and women with and without diagnosed cardiovascular disease. Clinical trial data suggest that HR reduction itself is an important mechanism of benefit of beta-blockers and other heart-rate lowering drugs used after acute myocardial infarction, in chronic heart failure, and in stable angina pectoris. Pathophysiological studies indicate that a relatively high HR has direct detrimental effects on the progression of coronary atherosclerosis, on the occurrence of myocardial ischemia and ventricular arrhythmias, and on left ventricular function. Studies have found a continuous increase in risk with HR above 60 beats/min. Although it may be difficult to define an optimal HR for a given individual, it seems desirable to maintain resting HR substantially below the traditionally defined tachycardia threshold of 90 or 100 beats/min. These findings suggest that the potential role of HR and its modulation should be considered in future cardiovascular guidance documents.

Abbreviations and Acronyms

AMI
acute myocardial infarction
HR
heart rate

Cited by (0)

All authors have received honoraria and many have received research grants from Servier Laboratories, and all authors are a part of the advisory board of ivabradine, a sinus node inhibiting agent for the management of angina. However, this article is entirely about the importance of heart rate and does not discuss ivabradine at all. None of the authors have received any financial support from Servier Laboratories for the preparation of this article.